Chemotherapy of Hodgkin's disease. Maintenance therapy vs no maintenance after remission induction with combination chemotherapy.
D000328:Adult; D000367:Age Factors; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D001772:Blood Cell Count; D001853:Bone Marrow; D005069:Evaluation Studies as Topic; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D008466:Mechlorethamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012075:Remission, Spontaneous; D012737:Sex Factors; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001565:Benzoates; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone